期刊文献+

雷洛昔芬对大鼠成骨细胞分泌细胞因子的影响 被引量:1

Effects of Raloxifene on cytokine secretion in osteoblasts in rats
下载PDF
导出
摘要 目的初步探讨雷洛昔芬对成骨细胞自分泌和旁分泌的作用机制。方法采用新生大鼠颅骨来源酶消化法体外培养成骨细胞,在培养液中加入不同浓度雷洛昔芬(0、10^-8、10^-7、10^-6mol/L),在共同条件下培养。应用酶联免疫法(EusA)测定细胞培养上清液中IL-1β、IL-6和TNF-α水平。结果雷洛昔芬(10^-8mol/L组和10^-7mol/L组)的IL-1β、IL-6值低于对照组,雷洛昔芬各组TNF-α值均高于对照组,3项测试指标在0~24h和24~48h组间比较无显著性差异。结论适当浓度下雷洛昔芬(10^-8M,10&-7M)抑制大鼠成骨细胞分泌IL-1β和IL-6,雷洛昔芬能够通过调节成骨细胞的自分泌及旁分泌影响破骨细胞的功能。雷洛昔芬促进大鼠成骨细胞分泌TNF-α,雷洛昔芬在体内对TNF-α分泌与调节的作用待进一步研究。 Objective To explore the mechanisms of the role of raloxifene on osteoblastic autocrine and paracrine. Methods Osteoblasts were isolated from the ealvaria of neonatal rats through trypsin and eollagenase digestion. Different concentrations of raloxifene (0,10^-8 M, 10^-7 M and 10^-6 mol/L) were added into the culture medium. The levels of IL-1β, IL-6 and TNF-α in the cultures media of rat nsteoblasts were measured by ELISA.Results The concentration of IL-1β and IL-6 in the groups with raloxifene, at 10^-8 M and 10^-7 M, were lower than those of the control, and the concentration of TNF-α in all raloxifene groups were higher than that of the control except for the raloxifene groups, at 10^-6 M, in the 0 - 24 hours. No significant difference was shown between the 0 - 24 hours and 24 - 48 hours' production of cytokines among any raloxifene group with the control group. Conclusions Certain concentrations of raloxifene (10^-8 M, 10^-7 M)could inhibit IL-1β and IL-6 secretion in rat osteoblasts and was able to affect the function of osteoclasts through modulating the autocrine and paracrine function of osteoblasts. Raloxifene can increase TNF-α production in rat osteoblasts iu vitro, however, more study is pending on its mechanism.
出处 《中国骨质疏松杂志》 CAS CSCD 2006年第6期607-611,共5页 Chinese Journal of Osteoporosis
关键词 雷洛昔芬 成骨细胞 骨形成 细胞因子 Raloxifene Osteoblasts Cytokines
  • 相关文献

参考文献20

  • 1Writing Group for the Women' Health Initiative Investigators.Risk and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women.JAMA,2002,288:321-333.
  • 2Ettubger B,Black DM,Mitlak BH,et al.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:results from a 3-years randomized clinical trial.Multiple Outcomes of Raloxifene Evaluation (MORE) investigators.JAMA,1999,7:637-645.
  • 3Manolagas SC.Role of cytokines in bone resorption.Bone,1995,17:63-67.
  • 4Passeri N,Girasole G,Jilka RL,et al.Increased interolenkin-6production by murine bone marrow and bone cells after estrogen withdrawl.Endocrinology,1993,133:822-828.
  • 5Ishimi Y,Miyaura C,Jin C,et al.IL-6 is produced by osteoblasts and induces bone resorption.J Immunol,1990,145:3297-3303.
  • 6Evans GL,Bryant Hu,Magee DE,et al.Raloxifene inhibition bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.Endocrinology,1996,137:4139-4144.
  • 7Viereck V,Grundker C,Blaschke S,et al.Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.J Clinical endocrinology & metabolism,2003,88:4206-4213.
  • 8Hikiji H,Ishii S,Shindou H,et al.Absence of platelet-activating factor receptor protects mice from osteoporosis following ovariectomy.J Clin Invest,2004,114:85-93.
  • 9Pacifici R,Rifas L,McCracken R,et al.Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interlenkin-1release.Proc Natl Acad Sci,1989,86:2398-2402.
  • 10Pacifici R,Brown C,Rifas L,et al.TNF-α and GM-CSF secretion from human blood monocytes:Effect of menopause and estrogen replacement.J Bone Miner Res,1990,5:145.

同被引文献10

  • 1Goodman S. Wear particulate and osteolysis [ J ]. Orthop Clin North Am, 2005, 36 : 41 - 48.
  • 2Purdue PE, Koulouvaris P, Potter HG, et al. The cellular and molecular biology of periprosthetic osteolysis [J]. Clin Orthop Relat Res, 2007, 454 : 251 - 261.
  • 3Vermes C, Chandrasekaran R, Jacobs JJ, et al. The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts [ J ]1. J Bone Joint Surg (AM), 2001, 83:201-211.
  • 4Vermes C, Chandrasekaran R, Dobai JG, et al. The com- bination of pamidronate and calcitriol reverses particle- and TNF-alphainduced altered functions of bone-marrow-derived stromal cells with osteoblastic phenotype [ J]. J Bone Joint Surg Br, 2004, 86 : 759 - 770.
  • 5Gallo , Mrazek F'Petrek M. Involvement of immunogenetic factors in the development of periprosthetic osteolysis[ J]. Acta Chir Orthop Tmttmatol Cech, 2007, 74:247 -252.
  • 6Konttinen YT, Xu JW, Waris E, et al. Interleukin-6 in a- septic loosening of total hip replacement prostheses [ J].Clin Exp Rheumatol, 2002, 20 : 485 - 490.
  • 7Stea S, isentin M, Granchi D, et al. Cytokines and oste- oIysis around total hip prostheses [ J]. Cytokine, 2000, 12:1575 - 1579.
  • 8Ragab AA, Nalepka JL, Bi Y, et al. Cytokines synergisti- cally induce osteoclast differentiation: support by immortal- ized or normal calvarial cells [ J ]. Am J Physiol Cell Physiol, 2002, 283 : C679 - C687.
  • 9Wong PK, Quinn JM, Sims NA, et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-in- duced osteoclastogenesis [ J ] Arthritis Rheum, 2006, 54:158 - 168.
  • 10Udagawa N, Takahashi N, Katagiri T, et al. Interleukin (IL) -6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic ceils but not on osteoclast progenitors [J]. J Exp Med, 1995, 182: 1461 - 1468.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部